Company
Headquarters: Paris, France
Employees: 28
CEO: Mr. Lloyd Diamond
€2.1 Million
EUR as of Jan. 1, 2024
US$2.3 Million
Company | Market Cap (USD) |
---|---|
Intuitive Surgical, Inc. | $113.81 B |
EssilorLuxottica SA | $90.57 B |
Becton, Dickinson and Company | $70.33 B |
HOYA Corp | $43.39 B |
Alcon Inc. | $37.65 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Pixium Vision SA has the following listings and related stock indices.
Stock: Euronext: ALPIX wb_incandescent
Stock: FSX: PXH wb_incandescent